Airain Ltd’s PTC Therapeutics PTCT Stock Holding History

Airain Ltd’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-27,790	Closed	-$273K	–	1006
2017 Q1	$273K	Buy	+27,790	New	+$336K	0.01%	649

Other funds holding PTCT

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Airain Ltd's PTCT Position: Q2 2017 in Review

Airain Ltd sold out of PTC Therapeutics (PTCT) in Q2 2017, closing a stake of 27,790 shares — an estimated $273K sold.

Airain Ltd first reported a position in PTCT in Q1 2017 and held it in 1 quarter. The position peaked at $273K in Q1 2017. 114 funds tracked by Wall St. Rank hold PTCT as of Q2 2017.

Airain Ltd reported no remaining PTC Therapeutics position as of Q2 2017 after selling out during the quarter.
Airain Ltd sold 27,790 PTC Therapeutics shares in Q2 2017, an estimated $273K.
Airain Ltd first reported a position in PTC Therapeutics in Q1 2017 and held it in 1 quarter.
Airain Ltd's PTC Therapeutics position peaked at $273K in Q1 2017.
114 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2017.

Based on Airain Ltd's 13F filing for Q2 2017, filed 8 Aug 2017.